Allan Sniderman

Summary

Publications

  1. ncbi request reprint The strengths and limitations of the apoB/apoA-I ratio to predict the risk of vascular disease: a Hegelian analysis
    Allan D Sniderman
    Mike Rosenbloom Laboratory for Cardiovascular Research, Room H7 22, Royal Victoria Hospital, McGill University Health Centre, 687 Pine Avenue West, Montreal, Quebec H3A 1A1, Canada
    Curr Atheroscler Rep 9:261-5. 2007
  2. ncbi request reprint Low-density lipoprotein lowering in type 2 diabetes mellitus: how to know how low to go
    Allan D Sniderman
    Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University, Montreal, Quebec, Canada
    Curr Opin Endocrinol Diabetes Obes 14:116-23. 2007
  3. doi request reprint When is equal not equal?
    Allan D Sniderman
    Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, Room H7 22, Royal Victoria Hospital, 687 Pine Avenue West, Montreal, Quebec H3A 1A1, Canada
    J Clin Lipidol 4:83-8. 2010
  4. ncbi request reprint Apolipoprotein B, apolipoprotein A-I, insulin resistance and the metabolic syndrome
    Allan D Sniderman
    Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Center, Royal Victoria Hospital, Montreal, Quebec, Canada
    Curr Opin Lipidol 18:633-7. 2007
  5. ncbi request reprint How, when, and why to use apolipoprotein B in clinical practice
    Allan D Sniderman
    Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, Laboratory for Cardiovascular Research, Royal Victoria Hospital, Montreal, Quebec, Canada
    Am J Cardiol 90:48i-54i. 2002
  6. pmc Temporal changes in concentrations of lipids and apolipoprotein B among adults with diagnosed and undiagnosed diabetes, prediabetes, and normoglycemia: findings from the National Health and Nutrition Examination Survey 1988-1991 to 2005-2008
    Earl S Ford
    Division of Population Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA, USA
    Cardiovasc Diabetol 12:26. 2013
  7. pmc Do statins lower testosterone and does it matter?
    Allan D Sniderman
    Division of Cardiology, McGill University Health Centre, 687 Pine Avenue West, Montreal, QC H3A 1A1, Canada
    BMC Med 11:58. 2013
  8. doi request reprint Discordance analysis of apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study
    Allan D Sniderman
    Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, Royal Victoria Hospital, Room H7 22, 687 Pine Avenue West, Montreal, Quebec, Canada H3A 1A1
    Atherosclerosis 225:444-9. 2012
  9. doi request reprint Comparison of coronary calcium screening versus broad statin therapy for patients at intermediate cardiovascular risk
    Allan D Sniderman
    Division of Cardiology, Royal Victoria Hospital, McGill University Health Centre, Montreal, Quebec, Canada
    Am J Cardiol 110:530-3. 2012
  10. doi request reprint Phenotypes of hypertriglyceridemia caused by excess very-low-density lipoprotein
    Allan D Sniderman
    Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, Room H7 22, Royal Victoria Hospital, 687 Pine Avenue West, Montreal, Quebec H3A 1A1, Canada
    J Clin Lipidol 6:427-33. 2012

Collaborators

Detail Information

Publications60

  1. ncbi request reprint The strengths and limitations of the apoB/apoA-I ratio to predict the risk of vascular disease: a Hegelian analysis
    Allan D Sniderman
    Mike Rosenbloom Laboratory for Cardiovascular Research, Room H7 22, Royal Victoria Hospital, McGill University Health Centre, 687 Pine Avenue West, Montreal, Quebec H3A 1A1, Canada
    Curr Atheroscler Rep 9:261-5. 2007
    ..Appreciating these distinctions should allow appropriate use of the apoB/apoA-I ratio as a simple, single, summary index of the lipoprotein-related risk of vascular disease...
  2. ncbi request reprint Low-density lipoprotein lowering in type 2 diabetes mellitus: how to know how low to go
    Allan D Sniderman
    Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University, Montreal, Quebec, Canada
    Curr Opin Endocrinol Diabetes Obes 14:116-23. 2007
    ..Getting it right means getting the target for therapy right, however. The article examines the criteria that should be used to make this choice...
  3. doi request reprint When is equal not equal?
    Allan D Sniderman
    Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, Room H7 22, Royal Victoria Hospital, 687 Pine Avenue West, Montreal, Quebec H3A 1A1, Canada
    J Clin Lipidol 4:83-8. 2010
    ..Our objective should be to learn how to combine the information from parameters rather than eliminate them and we need to focus on evaluation of risk in individuals and not just groups...
  4. ncbi request reprint Apolipoprotein B, apolipoprotein A-I, insulin resistance and the metabolic syndrome
    Allan D Sniderman
    Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Center, Royal Victoria Hospital, Montreal, Quebec, Canada
    Curr Opin Lipidol 18:633-7. 2007
    ..Therefore, our objective is to elucidate how apolipoprotein B and apolipoprotein A-I amplify evidence of the interactions amongst metabolic syndrome, insulin resistance, abdominal obesity, and vascular risk...
  5. ncbi request reprint How, when, and why to use apolipoprotein B in clinical practice
    Allan D Sniderman
    Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, Laboratory for Cardiovascular Research, Royal Victoria Hospital, Montreal, Quebec, Canada
    Am J Cardiol 90:48i-54i. 2002
    ....
  6. pmc Temporal changes in concentrations of lipids and apolipoprotein B among adults with diagnosed and undiagnosed diabetes, prediabetes, and normoglycemia: findings from the National Health and Nutrition Examination Survey 1988-1991 to 2005-2008
    Earl S Ford
    Division of Population Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA, USA
    Cardiovasc Diabetol 12:26. 2013
    ....
  7. pmc Do statins lower testosterone and does it matter?
    Allan D Sniderman
    Division of Cardiology, McGill University Health Centre, 687 Pine Avenue West, Montreal, QC H3A 1A1, Canada
    BMC Med 11:58. 2013
    ..We treat individuals not groups. Averages do not disclose enough about the risks and benefits of drugs. See related research article here http://www.biomedcentral.com/1741-7015/11/57...
  8. doi request reprint Discordance analysis of apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study
    Allan D Sniderman
    Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, Royal Victoria Hospital, Room H7 22, 687 Pine Avenue West, Montreal, Quebec, Canada H3A 1A1
    Atherosclerosis 225:444-9. 2012
    ..Accordingly, this study tests within the INTERHEART data base whether apoB or non-HDL-C are equivalent markers of risk when the two markers are discordant...
  9. doi request reprint Comparison of coronary calcium screening versus broad statin therapy for patients at intermediate cardiovascular risk
    Allan D Sniderman
    Division of Cardiology, Royal Victoria Hospital, McGill University Health Centre, Montreal, Quebec, Canada
    Am J Cardiol 110:530-3. 2012
    ..In conclusion, even in the short term, the broad statin prevention strategy would be at least as effective in decreasing clinical events but with greater net savings than a prevention strategy using coronary calcium screening...
  10. doi request reprint Phenotypes of hypertriglyceridemia caused by excess very-low-density lipoprotein
    Allan D Sniderman
    Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, Room H7 22, Royal Victoria Hospital, 687 Pine Avenue West, Montreal, Quebec H3A 1A1, Canada
    J Clin Lipidol 6:427-33. 2012
    ..To characterize the composition of very-low-density lipoprotein (VLDL) particles and the proportion of VLDL to total apolipoprotein B (apoB) particles in patients with hypertriglyceridemia caused by excess VLDL...
  11. doi request reprint Low-density lipoprotein-lowering strategies: target versus maximalist versus population percentile
    Allan D Sniderman
    Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, Montreal, Quebec, Canada
    Curr Opin Cardiol 27:405-11. 2012
    ..Moreover, it is increasingly assumed that the lower and lower is better and better approach is supported by unassailable evidence...
  12. doi request reprint Diagnosis and treatment of apolipoprotein B dyslipoproteinemias
    Allan Sniderman
    Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Center, Room H7 22, Royal Victoria Hospital, 687 Pine Avenue West, Montreal, QC H3A 1A1, Canada
    Nat Rev Endocrinol 6:335-46. 2010
    ..Here, we review the diagnostic algorithm for apoB dyslipoproteinemias and provide, for the first time, a treatment plan on the basis of a reduction of atherogenic lipoprotein particles rather than plasma lipids...
  13. ncbi request reprint Relation of age, the apolipoprotein B/apolipoprotein A-I ratio, and the risk of fatal myocardial infarction and implications for the primary prevention of cardiovascular disease
    Allan D Sniderman
    Mike Rosenbloom Laboratory for Cardiovascular Research, Royal Victoria Hospital, Montreal, Quebec, Canada
    Am J Cardiol 100:217-21. 2007
    ..In conclusion, it appears that not all of the effects of age are irreversible. therefore, outcomes with early prevention might be much more favorable than usually assumed...
  14. ncbi request reprint Apolipoprotein A1 and B
    Allan D Sniderman
    Mike Rosenbloom Laboratory for Cardiovascular Research, Room H7 22, McGill University Health Centre, 687 Pine Avenue West, Montreal, Quebec H3A 1A1, Canada
    Clin Lab Med 26:733-50. 2006
    ....
  15. doi request reprint Why is non-high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol?
    Allan Sniderman
    Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, Room H7 22, Royal Vic Hosp, 687 Pine Avenue West, Montreal, Quebec H3A 1A1, Canada
    J Clin Lipidol 4:152-5. 2010
    ..Rather, non-HDL-C appears to be an indirect way of estimating apoB. We argue that we should integrate the information from non-HDL-C and apoB for better risk assessment and a better target of therapy...
  16. doi request reprint A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk
    Allan D Sniderman
    Mike Rosenbloom Laboratory for Cardiovascular Research, Royal Victoria Hospital, McGill University Health Centre, 687 Pine Avenue West, Montreal, Quebec, Canada
    Circ Cardiovasc Qual Outcomes 4:337-45. 2011
    ..Whether apolipoprotein B (apoB) or non-high-density lipoprotein cholesterol (HDL-C) adds to the predictive power of low-density lipoprotein cholesterol (LDL-C) for cardiovascular risk remains controversial...
  17. doi request reprint Non-HDL C equals apolipoprotein B: except when it does not!
    Allan Sniderman
    Mike Rosenbloom Laboratory for Cardiovascular Research, Montreal, Quebec, Canada
    Curr Opin Lipidol 21:518-24. 2010
    ..Canada has chosen to do so. What Europe and America decide remains to be seen...
  18. doi request reprint Cardiovascular death in dialysis patients: lessons we can learn from AURORA
    Allan D Sniderman
    Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, Quebec, Canada
    Clin J Am Soc Nephrol 5:335-40. 2010
    ..Thus sudden death due to arrhythmia and slow progressive death due to heart failure could be manifestations of reperfusion injury...
  19. doi request reprint Targets for LDL-lowering therapy
    Allan Sniderman
    Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, Royal Victoria Hospital, Montreal, Quebec, Canada
    Curr Opin Lipidol 20:282-7. 2009
    ..The conventional approach is restricted to a comparison of in-trial data. Although essential, this overlooks the issue as to which marker better identifies residual risk after any particular treatment regimen...
  20. ncbi request reprint ApoB versus non-HDL-C: what to do when they disagree
    Allan Sniderman
    Mike Rosenbloom Laboratory for Cardiovascular Research, Room H7 22, Royal Victoria Hospital MUHC, Quebec, Canada
    Curr Atheroscler Rep 11:358-63. 2009
    ..These examples establish that apoB and non-HDL-C are not clinical equivalents...
  21. doi request reprint Age as a modifiable risk factor for cardiovascular disease
    Allan D Sniderman
    Mike Rosenbloom Laboratory for Cardiovascular Research, Royal Victoria Hospital, Montreal, Quebec, Canada
    Lancet 371:1547-9. 2008
  22. pmc Regulation of plasma LDL: the apoB paradigm
    Allan D Sniderman
    Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, Montreal, Quebec, Canada
    Clin Sci (Lond) 118:333-9. 2010
    ..The apoB paradigm includes both and points to a different model of how the hepatocyte achieves cholesterol homoeostasis in a complex metabolic environment...
  23. pmc The causal exposure model of vascular disease
    Allan D Sniderman
    Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, Montreal, QC, Canada
    Clin Sci (Lond) 122:369-73. 2012
    ..Preventing the development of advanced atherosclerotic lesions by treating the causes of vascular disease is the simplest, surest and most effective way to prevent clinical events...
  24. doi request reprint Levels of lipids and apolipoproteins in three cultures
    Amirreza Solhpour
    Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, Montreal, Quebec H3A 1A1, Canada
    Atherosclerosis 207:200-7. 2009
    ..The objective of this study was to demonstrate the additional information that can be acquired by comparing the major plasma lipids and apolipoproteins amongst adult male and female Swedes, Iranians and Americans...
  25. ncbi request reprint Visfatin concentration in Asian Indians is correlated with high density lipoprotein cholesterol and apolipoprotein A1
    Jessica Smith
    Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, Montreal, Canada
    Clin Endocrinol (Oxf) 65:667-72. 2006
    ..Visfatin is a recently described adipose tissue derived hormone whose role in humans remains largely unknown...
  26. ncbi request reprint Effect of increasing metabolic syndrome score on atherosclerotic risk profile and coronary artery disease angiographic severity
    B Charles Solymoss
    Montreal Heart Institute, McGill University Health Centre, Montreal, Quebec, Canada
    Am J Cardiol 93:159-64. 2004
    ..Therefore, the MS score provides a clinically useful index of MS severity and the associated atherosclerotic risk factor profile. It also correlates with the angiographic severity of CAD and its clinical complications...
  27. ncbi request reprint Is lower and lower better and better? A re-evaluation of the evidence from the Cholesterol Treatment Trialists' Collaboration meta-analysis for low-density lipoprotein lowering
    Allan Sniderman
    Mike Rosenbloom Laboratory for Cardiovascular Research, Room H7, 22, McGill University Health Centre, Royal Victoria Hospital, 687 Pine Avenue West, Montreal, Quebec, H3A 1A1 Canada
    J Clin Lipidol 6:303-9. 2012
    ..It follows that definitive evidence supporting maximal lowering of LDL-C or maximal dose of statins is still lacking and guidelines, if they are to be evidence-based, should acknowledge this uncertainty...
  28. ncbi request reprint Insights from apoB: from better diagnosis & therapy to the Medusa Hypothesis
    Allan Sniderman
    Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Center, Royal Victoria Hospital, 687 Pine Avenue West, Montreal, QC H3A 1A1, Canada
    Atheroscler Suppl 5:19-24. 2004
    ..The Medusa Hypothesis puts forward a common pathophysiology for the complex and biologically diverse array of factors that have been associated with vascular disease...
  29. pmc 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations
    Jacques Genest
    McGill University Health Centre, Montreal, Canada
    Can J Cardiol 25:567-79. 2009
    ..The present article represents the 2009 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult...
  30. ncbi request reprint Body composition and the apoB/apoA-I ratio in migrant Asian Indians and white Caucasians in Canada
    Jessica Smith
    Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, Royal Victoria Hospital, 687 Pine Avenue West, Montreal, Quebec, Canada H3A 1A1
    Clin Sci (Lond) 111:201-7. 2006
    ..It also relates differences in body fat distribution to differences in the apoB/apoA-I ratio, providing at least part of the answer as to why South Asians may be at increased risk of vascular disease...
  31. ncbi request reprint The adipocyte life cycle hypothesis
    Jessica Smith
    The Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, Royal Victoria Hospital, 687 Pine Avenue West, Montreal, Quebec H3A 1A1, Canada
    Clin Sci (Lond) 110:1-9. 2006
    ..This hypothesis may explain a variety of previously unanswered clinical puzzles such as the vulnerability of many peoples from South East Asia to the adverse metabolic consequences of obesity...
  32. ncbi request reprint Hypertriglyceridemic hyperapoB in type 2 diabetes
    Allan D Sniderman
    Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, McGill University, Montreal, Canada
    Diabetes Care 25:579-82. 2002
    ..In particular, there are few data on apoB levels in these patients. Moreover, most reports have focused on mean lipoprotein levels and consequently there is little information on the frequencies of the various dyslipidemic phenotypes...
  33. ncbi request reprint Familial combined hyperlipidaemia: how can genetic disorders be common, complex and comprehensible?
    Allan Sniderman
    Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University, Montreal, Quebec, Canada
    Clin Sci (Lond) 113:365-7. 2007
    ..The key feature of this model of common complex disease is that it posits testable faults in definable metabolic pathways, which supply the genetic underpinning of the disorder...
  34. ncbi request reprint Diagnosis of type III hyperlipoproteinemia from plasma total cholesterol, triglyceride, and apolipoprotein B
    Allan Sniderman
    Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, H7 22, Royal Victoria Hospital, MUHC, 687 Pine Avenue West, Montreal, Quebec, Canada H3A 1A1
    J Clin Lipidol 1:256-63. 2007
    ..Our objective was to develop a simple algorithm that could be applied in routine clinical practice to diagnose type III hyperlipoproteinemia based on plasma total cholesterol, triglyceride and apolipoprotein (Apo) B...
  35. pmc Bioprosthetic valve degeneration due to cholesterol deposition in a patient with normal lipid profile
    Leslie Price
    McGill University Health Centre, Montreal, Quebec
    Can J Cardiol 23:233-4. 2007
    ..It suggests that the characteristics of the valve are more critical than the patient's level of LDL-C...
  36. doi request reprint Initial results of posterior leaflet extension for severe type IIIb ischemic mitral regurgitation
    Benoit de Varennes
    McGill University Health Center, Montreal, Quebec, Canada
    Circulation 119:2837-43. 2009
    ..Management of severe ischemic mitral regurgitation remains difficult with disappointing early and intermediate-term surgical results of valve repair...
  37. ncbi request reprint Non-HDL cholesterol and apoB in dyslipidaemia
    Allan D Sniderman
    The Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, Royal Victoria Hospital, Montreal, QC, Canada
    Clin Sci (Lond) 114:149-55. 2008
    ..It follows that correlation is not adequate as a sole judge of equivalence of laboratory parameters...
  38. ncbi request reprint Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk
    Allan D Sniderman
    Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, Montreal, Quebec, Canada
    Am J Cardiol 91:1173-7. 2003
    ....
  39. ncbi request reprint Effects on apoB-100 secretion and bile acid synthesis by redirecting cholesterol efflux from HepG2 cells
    Allan D Sniderman
    Mike Rosenbloom Laboratories for Cardiovascular Research, Cardiovascular Genetics Laboratory, McGill University, Montreal, Canada
    J Lipid Res 44:527-32. 2003
    ..They also point to physiologically important, although still only partially understood, metabolic relationships amongst hepatic apoB-100 secretion, cholesterol efflux, and bile acid synthesis...
  40. ncbi request reprint Applying apoB to the diagnosis and therapy of the atherogenic dyslipoproteinemias: a clinical diagnostic algorithm
    Allan D Sniderman
    Laboratory for Cardiovascular Research, Royal Victoria Hospital, Montreal, Quebec, Canada
    Curr Opin Lipidol 15:433-8. 2004
    ..The second is to present a diagnostic algorithm for the apolipoprotein B100 dyslipidemias based on triglyceride and apoB...
  41. ncbi request reprint Fasting acylation-stimulating protein is predictive of postprandial triglyceride clearance
    Katherine Cianflone
    Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, Royal Victoria Hospital, 687 Pine Avenue, West Montreal, Quebec H3A 1A1, Canada
    J Lipid Res 45:124-31. 2004
    ..Plasma ASP may be useful as a fasting variable that will provide additional information regarding ppTG and NEFA clearance...
  42. ncbi request reprint Lipoprotein(a) and atherogenesis: a puzzle inside a riddle within an enigma
    Allan D Sniderman
    Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, McGill University, Montreal, Que
    Clin Invest Med 25:89-91. 2002
  43. ncbi request reprint Triglycerides and small dense LDL: the twin Achilles heels of the Friedewald formula
    Allan D Sniderman
    Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, McGill University, Montreal, Quebec, Canada
    Clin Biochem 36:499-504. 2003
  44. ncbi request reprint Is there value in liver function test and creatine phosphokinase monitoring with statin use?
    Allan D Sniderman
    Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University, Montreal, Quebec, Canada
    Am J Cardiol 94:30F-34F. 2004
    ..The conclusion that follows, based on the evidence in hand, is that although these programs were appropriate at the time statins were introduced, they are not appropriate now...
  45. ncbi request reprint What do we (not) know about apoB, type 2 diabetes and obesity?
    J Smith
    Department of Dietetics and Human Nutrition, McGill University, Montreal, Que, Canada
    Diabetes Res Clin Pract 69:99-101. 2005
  46. ncbi request reprint Why might South Asians be so susceptible to central obesity and its atherogenic consequences? The adipose tissue overflow hypothesis
    Allan D Sniderman
    Mike Rosenbloom Laboratory for Cardiovascular Research, Division of Cardiology, McGill University Health Science Centre, Royal Victoria Hospital, 687 Pine Avenue West, Montreal, Quebec, Canada
    Int J Epidemiol 36:220-5. 2007
    ....
  47. ncbi request reprint The apoB/apoA-I ratio and insulin resistance: sorting out the metabolic syndrome
    Allan D Sniderman
    Eur Heart J 28:2563-4. 2007
  48. ncbi request reprint Comparison of the associations of apolipoprotein B and low-density lipoprotein cholesterol with other cardiovascular risk factors in the Insulin Resistance Atherosclerosis Study (IRAS)
    Ken Williams
    Department of Medicine, University of Texas Health Science Center, San Antonio, USA
    Circulation 108:2312-6. 2003
    ..This study compares the associations of apolipoprotein B (apoB) and LDL cholesterol (LDLC) with a wide array of measures of these risk factors...
  49. ncbi request reprint The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk
    Goran Walldius
    King Gustaf V Research Institute, Karolinska Institute, Stockholm, Sweden
    Clin Chem Lab Med 42:1355-63. 2004
    ..Moreover, we examined whether any lipids, lipoproteins or cholesterol ratios add significant predictive information beyond that provided by the apoB/apoA-I ratio...
  50. ncbi request reprint Effect of aging and obesity on the expression of dyslipidaemia in children from families with familial combined hyperlipidaemia
    Ewoud ter Avest
    Department of Medicine, Division of General Internal Medicine, Radboud University, Nijmegen Medical Centre, Nijmegen, The Netherlands
    Clin Sci (Lond) 112:131-9. 2007
    ..However, aging-related post-maturation increases in adipose tissue mass also appear to contribute to an aggravation and/or modulation of this genetically determined apoB overproduction...
  51. ncbi request reprint Apolipoprotein B versus non-high-density lipoprotein cholesterol: and the winner is
    Allan D Sniderman
    Circulation 112:3366-7. 2005
  52. ncbi request reprint Does low-density lipoprotein size add to atherogenic particle number in predicting the risk of fatal myocardial infarction?
    Ingmar Jungner
    Department of Medicine, Clinical Epidemiology Unit, Karolinska Institute, Stockholm, Sweden
    Am J Cardiol 97:943-6. 2006
    ..The strongest single lipoprotein-related risk factor was the apo-B/apo-A-I ratio. In conclusion, these results provide further confirmation of the importance of determining apo-B and apo-A-I in routine clinical practice...
  53. ncbi request reprint Comparison of the associations of apolipoprotein B and non-high-density lipoprotein cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the Insulin Resistance Atherosclerosis Study
    Naveed Sattar
    Section of Vascular Biochemistry, North Glasgow Hospitals University NHS Trust, Glasgow Royal Infirmary, Glasgow, UK
    Circulation 110:2687-93. 2004
    ..Both apolipoprotein (apo)B and non-HDL cholesterol (NHDLC) have been proposed as an additional indicator to identify patients at higher risk in MetS patients...
  54. doi request reprint The editor's roundtable: expanded versus standard lipid panels in assessing and managing cardiovascular risk
    Destry Sulkes
    MedsiteCME, New York, New York, USA
    Am J Cardiol 101:828-42. 2008
  55. ncbi request reprint Non-HDL cholesterol versus apolipoprotein B in diabetic dyslipoproteinemia: alternatives and surrogates versus the real thing
    Allan D Sniderman
    Diabetes Care 26:2207-8. 2003
  56. ncbi request reprint Addition of glucose to an oral fat load reduces postprandial free fatty acids and prevents the postprandial increase in complement component 3
    Antonie J van Oostrom
    Department of Vascular Medicine, University Medical Center Utrecht, Utrecht, Netherlands
    Am J Clin Nutr 79:510-5. 2004
    ..C3 is the central component of the complement system and the precursor of acylation-stimulating protein (ASP). Insulin and ASP are principal determinants of free fatty acid (FFA) trapping by adipose tissue...
  57. ncbi request reprint Differential impact of plasma triglycerides on HDL-cholesterol and HDL-apo A-I in a large cohort
    André J Tremblay
    Lipid Research Center, CHUQ Research Center, Québec Québec, Canada
    Clin Biochem 40:25-9. 2007
    ..To examine the relationship between plasma triglycerides (TG) to HDL-cholesterol (HDL-C) or HDL apo A-I...
  58. ncbi request reprint Risk factors for cardiovascular disease in women
    Allan D Sniderman
    JAMA 294:2843-4; author reply 2844. 2005
  59. ncbi request reprint Influence of hepatic steatosis (fatty liver) on severity and composition of dyslipidemia in type 2 diabetes
    Frederico G S Toledo
    Division of Endocrinology and Metabolism, Department of Medicine, University of Pittsburgh, School of Medicine, Pennsylvania, USA
    Diabetes Care 29:1845-50. 2006
    ....
  60. doi request reprint We must prevent disease, not predict events
    Allan D Sniderman
    J Am Coll Cardiol 52:300-1. 2008